dc.contributor.author |
Jaumdally, S.
|
|
dc.contributor.author |
Tomasicchio, M.
|
|
dc.contributor.author |
Pooran, A.
|
|
dc.contributor.author |
Esmail, A.
|
|
dc.contributor.author |
Kotze, A.
|
|
dc.contributor.author |
Meier, S.
|
|
dc.contributor.author |
Wilson, L.
|
|
dc.contributor.author |
Oelofse, S.
|
|
dc.contributor.author |
Van der Merwe, C.
|
|
dc.contributor.author |
Roomaney, A.
|
|
dc.contributor.author |
Davids, M.
|
|
dc.contributor.author |
Suliman, T.
|
|
dc.contributor.author |
Joseph, R.
|
|
dc.contributor.author |
Perumal, T.
|
|
dc.contributor.author |
Scott, A.
|
|
dc.contributor.author |
Shaw, M.
|
|
dc.contributor.author |
Preiser, W.
|
|
dc.contributor.author |
Williamson, C.
|
|
dc.contributor.author |
Goga, Ameena Ebrahim
|
|
dc.contributor.author |
Mayne, E.
|
|
dc.contributor.author |
Gray, G.
|
|
dc.contributor.author |
Moore, P.
|
|
dc.contributor.author |
Sigal, A.
|
|
dc.contributor.author |
Limberis, J.
|
|
dc.contributor.author |
Metcalfe, J.
|
|
dc.contributor.author |
Dheda, K.
|
|
dc.date.accessioned |
2025-02-26T05:48:52Z |
|
dc.date.available |
2025-02-26T05:48:52Z |
|
dc.date.issued |
2024-03-05 |
|
dc.description |
DATA AVAILABILITY : All data generated and analyzed in this study are included in the paper and its Supplementary section. Individual participant datawill bemade available to researchers who provide a protocol that is approved by their respective human research ethics committee. All protocols will be reviewed and approved by the CAS COVID consortiumtrial steering committee up to five years following publication. A data sharing agreement (DTA) will need to be concluded between the representatives of the requesting institution and the University of Cape Town Lung Institute. Data sharing requests should be directed to keertan. dheda@uct.ac.za. Table S6 provides the accession codes for the WGS of the SARS-CoV-2 variants that could be sequenced for this study. The rawreads and rawcount file for the RNAseq experiment has been deposited on the GEO website under the accession number GSE252508. |
en_US |
dc.description.abstract |
Airborne transmission of SARS-CoV-2 aerosol remains contentious. Importantly,
whether cough or breath-generated bioaerosols can harbor viable and
replicating virus remains largely unclarified. We performed size-fractionated
aerosol sampling (Andersen cascade impactor) and evaluated viral culturability
in human cell lines (infectiousness), viral genetics, and host immunity in
ambulatory participants with COVID-19. Sixty-one percent (27/44) and 50%
(22/44) of participants emitted variant-specific culture-positive aerosols
<10μmand <5μm, respectively, for up to 9 days after symptom onset. Aerosol
culturability is significantly associated with lower neutralizing antibody titers,
and suppression of transcriptomic pathways related to innate immunity and
the humoral response. A nasopharyngeal Ct <17 rules-in ~40% of aerosol
culture-positives and identifies those who are probably highly infectious.
A parsimonious three transcript blood-based biosignature is highly predictive
of infectious aerosol generation (PPV > 95%). There is considerable heterogeneity
in potential infectiousness i.e., only 29% of participants were probably
highly infectious (produced culture-positive aerosols <5μm at ~6 days after
symptom onset). These data, which comprehensively confirm variant-specific
culturable SARS-CoV-2 in aerosol, informthe targeting of transmission-related
interventions and public health containment strategies emphasizing improved
ventilation. |
en_US |
dc.description.department |
Paediatrics and Child Health |
en_US |
dc.description.librarian |
am2024 |
en_US |
dc.description.sdg |
SDG-03:Good heatlh and well-being |
en_US |
dc.description.sponsorship |
The South African Medical Research Council; the Center for Emerging and Neglected Diseases; the European and Developing Countries Clinical Trials Partnership; UK Medical Research Council and the Wellcome Trust. |
en_US |
dc.description.uri |
https://www.nature.com/ncomms/ |
en_US |
dc.identifier.citation |
Jaumdally, S., Tomasicchio, M., Pooran, A. et al. 2024, 'Frequency, kinetics and determinants of viable SARS-CoV-2 in bioaerosols from ambulatory COVID-19 patients infected with the Beta, Delta or Omicron variants', Nature Communications, vol. 15, art. 2003, pp. 1-13. https://DOI.org/10.1038/s41467-024-45400-1. |
en_US |
dc.identifier.issn |
2041-1723 (online) |
|
dc.identifier.other |
10.1038/s41467-024-45400-1 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/101215 |
|
dc.language.iso |
en |
en_US |
dc.publisher |
Nature Research |
en_US |
dc.rights |
© The Author(s) 2024. Open access. This article is licensed under a Creative Commons Attribution 4.0 International License. |
en_US |
dc.subject |
Cough |
en_US |
dc.subject |
Transmission |
en_US |
dc.subject |
COVID-19 pandemic |
en_US |
dc.subject |
Coronavirus disease 2019 (COVID-19) |
en_US |
dc.subject |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
en_US |
dc.subject |
SDG-03: Good health and well-being |
en_US |
dc.subject |
Airborne transmission |
en_US |
dc.title |
Frequency, kinetics and determinants of viable SARS-CoV-2 in bioaerosols from ambulatory COVID-19 patients infected with the Beta, Delta or Omicron variants |
en_US |
dc.type |
Article |
en_US |